Sucampo Pharmaceuticals — Q3 2017 Earnings Presentation
28 slides from Sucampo Pharmaceuticals's earnings presentation, Nov 1, 2017
Slide 1: Third Quarter 2017 Corporate Update and Financial Results
November 1, 2017 Third Quarter 2017 Corporate Update and Financial Results 1
Slide 2: Introductions and Forward-Looking Statements
Introductions and Forward - Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs 2
Slide 3: Agenda
Agenda Introductions and Forward - Looking Statements Silvia Taylor Corporate Update Peter Greenleaf Pipeline Update Peter Kiener, D. Phil Financial Update Peter Pfreundschuh Closing Remarks Peter Greenleaf 3
Slide 4: Forward Looking Statement
Forward Looking Statement This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to dif fer
Slide 5: Non-GAAP Metrics
Non - GAAP Metrics This presentation contains four financial metrics (Adjusted Net Income, EBITDA, Adjusted EBITDA and Free Cash Flow) that are con sidered “non - GAAP” financial metrics under applicable Securities and Exchange Commission rules and regulations. These non - GAAP financial metr ics sh
Slide 6: Q3 2017
Q3 2017 Corporate Update Peter Greenleaf, Chairman and CEO 6
Slide 7: Significant Corporate Progress
Significant Corporate Progress • Advanced key pipeline programs • VTS - 270 – Pivotal data read - out in Niemann - Pick Disease in 2018 • CPP - 1X/sulindac fixed dose combination • FDA accepted filing for AMITIZA in pediatric functional constipation in children 6 - 17 years of age, with Priority Rev
Slide 8: Guidance Increased for 2017
Guidance Increased for 2017 • Revised guidance includes milestone of $10 million from Mylan expected in fourth quarter 8 Current Previous Total Revenue $250 to $255 million $220 to $230 million Adjusted Net Income $63 to $68 million $56 to $66 million Adjusted EBITDA $120 to $125 million $109 to $11
Slide 9: VTS-270 Program Update
VTS - 270 Program Update • VTS - 270 for the treatment of Niemann - Pick Disease (NPC - 1) in global pivotal registration program • Ultra - rare disorder with devastating and ultimately fatal outcome • Orphan drug designation in both U.S. and Europe and breakthrough therapy designation in U.S. • Pha
Slide 10: CPP-1X/sulindac Phase 3 Program Update
CPP - 1X/sulindac Phase 3 Program Update • In Phase 3 program for the treatment of Familial Adenomatous Polyposis (FAP) • Rare disease that leads to cancer of GI tract in 100% of patients • Partnership with Cancer Prevention Pharmaceuticals • Fast - Track status granted by FDA • If relevant criteria
Slide 11: Strong Q3 2017 U.S. AMITIZA Performance
Strong Q3 2017 U.S. AMITIZA Performance • Takeda’s AMITIZA net sales for royalty calculation purposes • Q3 grew 6% YoY to $115.2M • Driven by increased volume and price • Royalty revenue grew 11% YoY to $23.0M • U.S. AMITIZA product sales to Takeda of $13.1M • Total U.S. revenue of $36.2M • AMITIZA
Slide 12: Strong Japan AMITIZA Performance
Strong Japan AMITIZA Performance • Sucampo Q3 revenue: $20.5M, growth of 18% YoY • Growth driven by volume • Increased 35% YoY • Patient demand for AMITIZA remains strong in an increasingly competitive market • Expect AMITIZA to continue to hold solid position with prescribers and benefit from incre
Slide 13: Pipeline Update
Pipeline Update Peter Kiener, D. Phil, CSO 13 13
Slide 14: VTS-270 for Treatment of NPC-1
VTS - 270 for Treatment of NPC - 1 14 Until regulatory decision • IT injections every 2 weeks • Trial fully enrolled • All patients currently in parts B or C • Part B is key phase for NDA submission; completes end of March 2018 • Pivotal data expected in mid - 2018 • Potential regulatory approval in
Slide 15: CPP-1X/sulindac for Treatment of FAP
CPP - 1X/sulindac for Treatment of FAP • CPP - 1X/sulindac is being developed to treat Familial Adenomatous Polyposis (FAP), a predominately genetic disease • If left untreated, FAP eventually develops into colon cancer in 100% of patients • Orphan disease in U.S. and Europe • Ongoing Phase 3 study
Slide 16: AMITIZA for Treatment of Pediatric Functional Constipation
AMITIZA for Treatment of Pediatric Functional Constipation • FDA accepted sNDA filing for life cycle management program for AMITIZA in children age 6 - 17 with pediatric functional constipation • Priority Review designation • PDUFA date Jan 28, 2018 • Ongoing commitment to pediatric functional const
Slide 17: Product Pipeline
Product Pipeline 17 Sucampo Program Option Program Target First Indication Development Stage (s)NDA/MAA Filing Approval AMITIZA CIC2 Pediatric functional constipation (6 - 17 yrs.) P3 2017 2018 CPP - 1X/sulindac combination product Polyamines Familial Adeneomatous Polyposis P3 2018/19 2019 VTS - 270
Slide 18: Financial Update
Financial Update Peter Pfreundschuh, CFO 18 18
Slide 19: Financial and Operational Performance Summary of Results
Financial and Operational Performance Summary of Results Q3 - 17 Q3 - 16 Net Income GAAP $10.4M $8.1M EPS GAAP – diluted $0.19 $0.19 EBITDA $27.4M $35.6M Adjusted Net Income $15.8M $12.9M Adjusted EPS – diluted $0.27 $0.30 Adjusted EBITDA $30.8M $30.0M 19
Slide 20: Q3 Adjusted Net Income
Q3 Adjusted Net Income $ sucampo
Slide 21: Q3 Adjusted EBITDA
Q3 Adjusted EBITDA ae $ sucampo
Slide 22: Q3 Revenue
Q3 Revenue 22 61.3 3.1 2.3 2.2 2.3 1.9 57.9 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 Q3 2016 Amitiza Japan product sales Amitiza US royalty Amitiza US product sales Collaboration revenue Other Q3 2017
Slide 23: Key Balance Sheet Items
Key Balance Sheet Items 23 Balance Sheet End 9/30/17 Change End 12/31/16 Cash, Cash Equivalents and Restricted Cash $75M ($123.5M) $198.5M Notes Payable $291.9M $1.4M $290.5M Net Debt $216.9M $124.9M $92.0M • Decrease in cash primarily due to Vtesse acquisition and timing associated with working cap
Slide 24: Closing Remarks
Closing Remarks Peter Greenleaf, Chairman and CEO 24 24
Slide 25: 2017 Areas of Focus
2017 Areas of Focus 1. Deliver strong financial performance 2. Accelerate priority clinical programs 3. Evaluate and execute on additional opportunities for growth 25
Slide 26: Q&A Session
Q&A Session 26
Slide 27: Reconciliation of GAAP Net Income to Non-GAAP Net Income
Reconciliation of GAAP Net Income to Non - GAAP Net Income 27 RECONCILIATION OF GAAP NET INCOME TO ADJUSTED NET INCOME (in thousands, except per share amounts) Three Months Ended Three Months Ended September 30, 2017 September 30, 2016 Adjusted Net Income: GAAP net income 10,367 8,092 Amortization o
Slide 28: Reconciliation of Income from Operations to Adjusted EBITDA
Reconciliation of Income from Operations to Adjusted EBITDA 28 RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA (in thousands) Three Months Ended Three Months Ended September 30, 2017 September 30, 2016 GAAP net income 10,367 8,092 Adjustments: Income taxes 7,204 7,410 Interest expense 2,956 5,8
Sucampo Pharmaceuticals — Q3 2017 Earnings Presentation on 6ix